Drugs / 268664
268664
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00430534 | — | Epstein-Barr virus infection | Henogen | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 268664 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00430534 ↗ |
| Known as | gp350 vaccine | “Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized,” PMID 18190254 ↗ Dec 2007 |
| Known as | gp350/AS04 vaccine | “there were no concerns regarding the safety or reactogenicity of the gp350/AS04 vaccine.” PMID 18190254 ↗ Dec 2007 |
| Known as | Recombinant gp350 vaccine | “Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized,” PMID 18190254 ↗ Dec 2007 |
| Modality | Vaccine | “recombinant EBV subunit glycoprotein 350 (gp350)/aluminum hydroxide and 3-O-desacyl-4'-monophosphoryl lipid A (AS04) candidate vaccine” PMID 18190254 ↗ Dec 2007 |
| Route | Intramuscular | “Injected intramuscularly” NCT00430534 ↗ |